Protocol Ledger

NCT04264442 · Phase II · TERMINATED

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Interventional Phase II clinical trial protocol NCT04264442 sponsored by Fulcrum Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-13 Enrollment: 76 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04264442
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)76 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04264442
Protocol FieldVerified Registry Value
NCT IdentifierNCT04264442
Consolidated Lead SponsorFulcrum Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment76 participants (ACTUAL)
Registered Start Date2020-02-13
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI